FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and six months ended June 30, 2009. For the three months ended June 30, 2009, the Company reported a net loss of $6.3 million, or $(0.32) per diluted share, compared to a net loss of $9.2 million, or $(0.50) per diluted share, for the same period in 2008. For the six months ended June 30, 2009, the Company reported a net loss of $14.3 million, or $(0.75) per diluted share, compared to a net income of $22.1 million, or $1.15 per diluted share, for the same period in 2008. The net income for the three and six months ended June 30, 2008 included a gain of $39.3 million resulting from the January 2008 sale of the Company’s orofacial therapeutic business; excluding this gain, the Company’s net loss for six months ended June 30, 2008 was $17.2 million, or $(0.89) per diluted share. The Company ended the second quarter of 2009 with $62.2 million of cash, cash equivalents and investments, excluding auction rate securities.
